Adenosine and dopamine (DA) strongly modulate the neuronal activity in the striatum by pre-
and postsynaptic mechanisms. As several behavioral and molecular studies indicate a …

Abnormalities in dopaminergic control of basal ganglia function play a key role in
Parkinson's disease. Adenosine appears to modulate the dopaminergic control in striatum …

Basal ganglia processing results from a balanced activation of direct and indirect striatal
efferent pathways, which are controlled by dopamine D1 and D2 receptors, respectively …

Dopamine release is regulated by presynaptic dopamine receptors and interactions
between adenosine and dopamine receptors have been well documented. In the present …

It has been shown that striatal adenosine A2A receptors can antagonistically interact with
dopamine D2 receptors at the membrane level leading to a decrease in the affinity and …

Adenosine A2A receptors (A2ARs) are highly concentrated in the striatum. Two
pharmacological different functional populations of A2ARs have been recently described …

Prefrontal cortex (PFC) circuits are modulated by dopamine acting on D1‐and D2‐like
receptors, which are pharmacologically exploited to manage neuropsychiatric conditions …

To clarify differences in the operating mechanisms of adenosine receptor subtypes (A1 and
A2), striatal extracellular dopamine levels under various conditions were determined by in …

A2A adenosine receptor antagonists are currently under investigation as potential
therapeutic agents for Parkinson's disease (PD). However, the molecular mechanisms …

A very significant density of adenosine A2A receptors (A2ARs) is present in the striatum,
where they are preferentially localized postsynaptically in striatopallidal medium spiny …